论文部分内容阅读
1972年Danzinger及Bell等报道在胆囊功能良好时,长时期应用鹅脱氧胆酸(Chenodeoxycholicacid或CDCA)有明显溶解胆石的效能,但有肝脏损害及腹泻等副作用,使其临床应用受到限制。熊脱氧胆酸(Ursodeoxycholic acid或UDCA)在日本作为利胆药物已20余年。UDCA是CDCA的异构体,存在于熊的胆汁中,而在人胆汁中含量极少。采用CDCA治疗胆石症时,发现胆汁中UDCA含量有所增加。UDCA使胆汁中的胆固醇饱和度减低,并可溶解胆固醇性胆石。本文报道近2年来对胆石症患者用UDCA治疗的临床经验。胆石症患者74例(男19例,女55例),平均年龄48岁,胆囊功能均属良好。临床所用UDCA每片50毫克,口服每日3次,每次3片。在治疗过程中,不用其它利胆药物或抗胆固醇药物。 74例患者经UDCA治疗6～24个月(平均8.5月),胆石完全消失者16例,部分溶解16例,无变化35例,手术7例。前2组列为有效,有效率达32/74
In 1972, Danzinger and Bell et al. Reported that long-term use of Chenodeoxycholicacid (CDCA) has obvious effect of dissolving gallstones when gallbladder function is good, but side effects such as liver damage and diarrhea have limited its clinical application. Ursodeoxycholic acid (Ursodeoxycholic acid or UDCA) has been used as a gallbladder drug in Japan for more than 20 years. UDCA is an isoform of CDCA, present in the bile of bears, and very little in human bile. CDCA treatment of cholelithiasis, found in the bile UDCA content increased. UDCA reduces bile cholesterol saturation and dissolves cholesterol gallstones. This article reports the clinical experience of treatment of patients with cholelithiasis with UDCA in the past two years. 74 patients with cholelithiasis (19 males and 55 females), mean age 48 years, gallbladder function are good. UDCA clinical use of 50 mg per tablet, oral 3 times a day, each 3. In the course of treatment, no other cholesterol drugs or anti-cholesterol drugs. Totally 74 patients were treated with UDCA for 6 to 24 months (average 8.5 months). Sixteen cases of gallstone completely disappeared, 16 cases partially dissolved, 35 cases remained unchanged, and 7 cases operated. The first two groups as valid, effective rate of 32/74